Read by QxMD icon Read

Myocardial infarction type 2

Satu Strausz, Aki S Havulinna, Tiinamaija Tuomi, Adel Bachour, Leif Groop, Antti Mäkitie, Seppo Koskinen, Veikko Salomaa, Aarno Palotie, Samuli Ripatti, Tuula Palotie
OBJECTIVE: To evaluate if obstructive sleep apnoea (OSA) modifies the risk of coronary heart disease, type 2 diabetes (T2D) and diabetic complications in a gender-specific fashion. DESIGN AND SETTING: A longitudinal population-based study with up to 25-year follow-up data on 36 963 individuals (>500 000 person years) from three population-based cohorts: the FINRISK study, the Health 2000 Cohort Study and the Botnia Study. MAIN OUTCOME MEASURES: Incident coronary heart disease, diabetic kidney disease, T2D and all-cause mortality from the Finnish National Hospital Discharge Register and the Finnish National Causes-of-Death Register...
October 15, 2018: BMJ Open
Eran Ni, Lingling Zhao, Na Yao, Xiaofang Zhu, Hong Cao, Shuzhen Sun, Weizhong Zhu
Bcl-2-associated athanogene3(BAG3) protects the heart and cardiomyocytes from ischaemia/reperfusion (I/R) injury. Although theanti-apoptosis effect of BAG3 has been demonstratedin multiple cell types, the structural domain of BAG3,which is responsible for its anti-apoptosis effect, is not well understood. BAG3 protein consists of various characteristic amino acid motifs/regions that permit the interaction of BAG3 with numerous proteins involved in many cellular key pathways.The purpose of this study is to determine whether theproline-rich (PXXP) domain of BAG3 is necessary for its cellular protection againsthypoxia-reoxygenation (H/R) stress by binding to its chaperone,heat shock cognate 71 kDa protein (HSC70)...
October 16, 2018: Clinical and Experimental Pharmacology & Physiology
David P Fisher, Eric Johnson, Sebastien Haneuse, David Arterburn, Karen J Coleman, Patrick J O'Connor, Rebecca O'Brien, Andy Bogart, Mary Kay Theis, Jane Anau, Emily B Schroeder, Stephen Sidney
Importance: Macrovascular disease is a leading cause of morbidity and mortality for patients with type 2 diabetes, and medical management, including lifestyle changes, may not be successful at lowering risk. Objective: To investigate the relationship between bariatric surgery and incident macrovascular (coronary artery disease and cerebrovascular diseases) events in patients with severe obesity and type 2 diabetes. Design, Setting, and Participants: In this retrospective, matched cohort study, patients with severe obesity (body mass index ≥35) aged 19 to 79 years with diabetes who underwent bariatric surgery from 2005 to 2011 in 4 integrated health systems in the United States (n = 5301) were matched to 14 934 control patients on site, age, sex, body mass index, hemoglobin A1c, insulin use, observed diabetes duration, and prior health care utilization, with follow-up through September 2015...
October 16, 2018: JAMA: the Journal of the American Medical Association
Margarita Alonso Fernández
In patients with type 2 diabetes, tight glycemic control prevents or delays the develop-ment of microvascular complications. In contrast, there is continued debate on the effect of macrovascular complications and the role of early glycaemic control on the ensuing cardiovascular disease. Although large randomised clinical trials have not shown a clearly beneficial effect of intensive control in the short term, subsequent follow-up studies of participants in these trials suggest a favourable cardiovascular effect in the long term...
June 2018: Semergen
Audrey Dionne, Nagib Dahdah
Kawasaki disease (KD) is an inflammatory febrile illness of early childhood and the primary cause of acquired heart disease during childhood. Coronary artery aneurysms (CAA) are a serious complication of KD, leading to ischemic heart disease, myocardial infarction, and sudden cardiac death. Timely diagnosis in the first ten days of fever is crucial to reduce the risk of coronary artery complications. Nitrogen-terminal B-type natriuretic peptide (NT-proBNP), originally used for the management of adults with heart disease, was shown to be useful in the diagnosis and management of patients with KD...
October 12, 2018: Children
A A Karpenko, V B Starodubtsev, P V Ignatenko, Sh B Saaia, A A Rabtsun
The study was undertaken to evaluate the efficacy and safety of endovascular interventions in the treatment of stenoses and occlusions of the brachiocephalic trunk (BCT). Described in the article are the results of retrospectively analysing the efficacy of endovascular interventions performed in a total of forty-five patients presenting with lesions of the BCT. Depending on the type of the BCT lesion, the patients were divided into 2 groups: Group One consisted of 28 patients diagnosed with stenoses of the BCT and Group Two included 17 patients found to have occlusions of the BCT...
2018: Angiologii︠a︡ i Sosudistai︠a︡ Khirurgii︠a︡, Angiology and Vascular Surgery
Jing Yu, Xufen Cao, Ye Zheng, Liqiu Yan, Jiawang Wang
The present study aimed to investigate the expression of microRNA (miR)‑133a in patients with or without acute myocardial infarction (AMI) following radical surgery for gastric cancer, and to explore its underlying mechanisms. Blood samples were collected from patients with or without AMI in order to detect the expression levels of miR‑133a and endothelial injury markers. In addition, an AMI rat model was established. Reverse transcription‑quantitative polymerase chain reaction was used to detect the mRNA expression levels of miR‑133a and B‑cell lymphoma 2‑like 1 (Bcl2l1)...
October 10, 2018: Molecular Medicine Reports
Juan Li, Liangliang Wang, Qian Wang, Zhaoqin Xin, Yilin Liu, Qinghua Zhao
Hypersensitive C-reactive protein (hs-CRP) is reported to be significant risk indicators not only for the development of cardiovascular disease, but also for the development or progression of type 2 diabetes. The objective of this study was to analyze the significance of hs-CRP in type 2 diabetes mellitus (T2DM) combined with acute myocardial infarction (AMI).Fifty patients with both T2DM and AMI, 50 patients with T2DM alone, and 50 healthy subjects (control group) were selected.Operating characteristic (ROC) analysis revealed that the sensitivity, specificity, accuracy, and critical value in the diagnosis of T2DM combined with AMI using hs-CRP level were 84...
October 2018: Medicine (Baltimore)
Mengxin Cai, Qing'an Wang, Zhiwei Liu, Dandan Jia, Rui Feng, Zhenjun Tian
AIMS: Myocardial infarction (MI) is accompanied with skeletal muscle abnormalities. The aims are to explore an optimal exercise mode to improve cardiac function and prevent skeletal muscle atrophy, and detected the possible mechanisms of exercise-induced inhibition of muscle atrophy. MAIN METHODS: Rats were subjected to four weeks of different types of exercise after MI surgery (resistance training, RT; moderated-intensity continuous aerobic exercise, MCE and high-intensity intermittent aerobic exercise, HIA)...
October 9, 2018: Life Sciences
Maria Isabel Smáradóttir, Sergiu-Bogdan Catrina, Kerstin Brismar, Anna Norhammar, Viveca Gyberg, Linda G Mellbin
PURPOSE: Copeptin and insulin-like growth factor binding protein-1 analysed at admission for a myocardial infarction in patients with type 2 diabetes mellitus predicts cardiovascular events. The present aim was to study the association between copeptin and insulin-like growth factor binding protein-1, the development of the levels over time, and if the predictive value remained when measured at hospital discharge and 3 months thereafter. METHODS: Copeptin and insulin-like growth factor binding protein-1 were analysed in patients (median age = 70, male = 68%) with type 2 diabetes mellitus + myocardial infarction at admission (n = 393), discharge (n = 309) and 3 months later (n = 288)...
October 11, 2018: Diabetes & Vascular Disease Research
Peter A Kavsak, Andrew Worster, Stephen A Hill, Allan S Jaffe
BACKGROUND: International recommendations on high-sensitivity cardiac troponin (hs-cTn) testing recommend that laboratories select only one sample type for testing. We evaluated the Siemens ADVIA Centaur hs-cTnI assay in serum and thereby provide information on imprecision, long-term storage stability, freeze-thaw stability, method comparison to other hs-cTnI assays, and clinical performance. METHODS: Patients with chest pain onset <6 h who already had Roche hs-cTnT, Beckman hs-cTnI and Abbott hs-cTnI results recorded and had non-thawed and frozen serum aliquots formed the study population (n = 134 patients with 305 serum aliquots obtained at either 0, 3 or 6 h stored below -70 °C since 2003) for measurement with the Siemens hs-cTnI assay in 2018...
October 6, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
Rebecca Sorber, Andrew Lehman, Husain N Alshaikh, Christopher J Abularrage, James H Black, Ying Wei Lum
BACKGROUND: The burden of metabolic syndrome (MetS) is increasing in the United States and is pervasive among patients with peripheral arterial disease. Whereas MetS has been implicated in the development of all types of cardiovascular disease and adverse outcomes after vascular interventions, little is known about how MetS influences perioperative outcomes of lower extremity bypass surgery and whether any negative effects can be modified by use of cardiovascular risk-modifying medications...
October 3, 2018: Journal of Vascular Surgery
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville, Karl M Thorpe, John J V McMurray, Stefano Del Prato
BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries...
October 1, 2018: Lancet
F Huet, H Vernhet, F Roubille
We report the case of a type-2 myocardial infarction immediately after renal denervation. The patient was followed for coronary artery disease. Low blood pressures were responsible for inferior acute myocardial infarction that revealed a sub occlusive stenosis of the right coronary artery.
October 2, 2018: Annales de Cardiologie et D'angéiologie
Christopher P Cannon, Darren K McGuire, Richard Pratley, Sam Dagogo-Jack, James Mancuso, Susan Huyck, Bernard Charbonnel, Weichung J Shih, Silvina Gallo, Urszula Masiukiewicz, Gregory Golm, Francesco Cosentino, Brett Lauring, Steven G Terra
BACKGROUND: Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major adverse CV events: time to the first event of CV death, nonfatal myocardial infarction, or nonfatal stroke. Secondary objectives are to demonstrate superiority of ertugliflozin versus placebo on time to: 1) the composite outcome of CV death or hospitalization for heart failure (HF); 2) CV death; and 3) the composite outcome of renal death, dialysis/transplant, or doubling of serum creatinine from baseline...
September 5, 2018: American Heart Journal
Ming-Hui Tai, Jason Shepherd, Hollie Bailey, Nathan Williams, Hatz Maximilian, Ignasi Campos Tapias, David Catterick, Gavin Worth
OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 antibody inhibitors (PCSK9i) are approved as adjuncts to maximal tolerated statin therapy to lower low-density lipoprotein cholesterol (LDL-C). This study describes real-world use, characteristics of PCSK9i users and non-users, and factors influencing treatment choice. METHODS: A physician and patient survey was conducted in Germany, Spain, and United Kingdom (UK) from December 2016 to April 2017 through the Adelphi Dyslipidemia Disease Specific Programme...
October 5, 2018: Current Medical Research and Opinion
Andrew R Chapman, Nicholas L Mills
No abstract text is available yet for this article.
September 11, 2018: Circulation
Robbert J de Winter, Jaya Chandrasekhar, Deborah N Kalkman, Melissa B Aquino, Pier Woudstra, Marcel A Beijk, Samantha Sartori, Usman Baber, Jan G Tijssen, Karel T Koch, George D Dangas, Antonio Colombo, Roxana Mehran
OBJECTIVES: The aim of this study was to evaluate 1-year clinical safety and efficacy of the dual-therapy COMBO stent in a large, all-comers patient-level pooled cohort. BACKGROUND: The COMBO stent (OrbusNeich Medical, Fort Lauderdale, Florida) is a novel stent with abluminal sirolimus elution from a biodegradable polymer and a luminal pro-healing anti-CD34+ antibody layer, which attracts circulating endothelial progenitor cells. These endothelial progenitor cells can quickly mature into normal endothelium, providing rapid endothelialization...
October 8, 2018: JACC. Cardiovascular Interventions
Stephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen Dungan, Maria C Faingold, Michael E Farkouh, Denise R Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F Merino-Torres, Michael A Nauck, Sue D Pedersen, Wayne Huey-Herng Sheu, Robert J Silver, Cees J Tack, Nikhil Tandon, Ole K Jeppesen, Mette Strange, Mette Thomsen, Mansoor Husain
AIM: To assess the cardiovascular safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agonist. METHODS: PIONEER 6 is a multinational, randomised, placebo-controlled, double-blind trial in patients with type 2 diabetes (T2D) at high risk of cardiovascular events (defined as being: [1] ≥50 years and having established cardiovascular disease or moderate (Stage 3) chronic kidney disease [CKD], or [2] ≥60 years with ≥1 other cardiovascular risk factor)...
October 4, 2018: Diabetes, Obesity & Metabolism
Taek Kyu Park, Hye Bin Gwag, So Jin Park, Hyejeong Park, Danbee Kang, Jinkyeong Park, Joongbum Cho, Chi Ryang Chung, Kyeongman Jeon, Gee Young Suh, Eliseo Guallar, Juhee Cho, Jeong Hoon Yang
BACKGROUND: The long-term prognosis of vasospastic angina (VSA) patients presenting with aborted sudden cardiac death (ASCD) is still unknown. We sought to compare the long-term clinical outcomes between VSA patients presenting with and without ASCD by retrospective analysis of a nationwide population-based database. METHODS: A total of 6972 patients in the Health Insurance Review and Assessment database who were hospitalized in the intensive care unit with VSA between July 1, 2007 and May 31, 2015 were enrolled...
September 27, 2018: International Journal of Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"